ArticleThe AAPS journal2010
AIDS treatment with novel anti-HIV compounds improved by nanotechnology.
Article in The AAPS journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 12 citations in OpenAlex.
- Advancement of the Emerging Field of RNA Nanotechnology.ACS nano · 2017Review
- Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro.The AAPS journal · 2014Article
- Nanotechnology and the treatment of HIV infection.Viruses · 2012Review
- Epigenetic modulation of human breast cancer by metallofullerenol nanoparticles: in vivo treatment and in vitro analysis.Nanoscale · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
The first International Symposium of Nanomedicine on AIDS "AIDS Treatment with Novel Anti-HIV compounds Improved by Nanotechnology" was held November 19-20, 2009 in Beijing, China. This symposium provided an international forum for presentation and discussion of exciting new advances in the emerging research area of nanobiomedical research on AIDS treatment as the focus point, as well as some issues in relevant fields such as nanobiomedical research on tumor treatment and safety evaluation of nanomedicines. Key highlights of the symposium include (1) reviewing current status of nanobiotechnology programs and their relations, more or less, with AIDS treatment; (2) reviewing current AIDS epidemiology in China and examining effectiveness and efficiency of current prevention and treatment strategies; (3) highlighting the obstacles to improve AIDS prevention and treatment, and (4) exploring innovative ways for nanotechnology to advance AIDS treatment, especially to combat HIV resistance to drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.